Objective. Activation of osteoclastogenesis at the bone site in rheumatoid arthritis (RA) is well established. The mechanisms by which circulating osteoclast precursors contribute are still unclear. Peroxisome proliferator-activated receptor γ coactivator 1β (PGC-1β) is implicated in transcriptional regulation of osteoclastogenesis in mouse models. This study was undertaken to investigate the contribution of PGC-1β to circulating osteoclast precursors and its link to bone destruction in RA.
INTRODUCTION
Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by progressive joint destruction leading to functional disability (1) . More than 45% of patients with early RA are reported to have bone erosion at an early stage (2) . Overproduction and activation of osteoclasts at the local site are responsible for bone erosion in RA (3) . Osteoclast precursors derive from human peripheral blood monocytes, and their differentiation occurs in vitro in the presence of RANKL and macrophage colony-stimulating factor (M-CSF) (4) . The contribution of monocyte-derived osteoclast precursors in vivo is unclear. Previous in vitro studies showed | 1253 that osteoclast differentiation from peripheral blood monocytes was enhanced in patients with RA compared to healthy controls (5, 6) . The identification of mechanisms leading to an association between circulating activation and actual bone destruction may represent a new target for treatment in diseases, such as RA, that are associated with increased activation of osteoclasts.
Changes in intracellular metabolic pathways in immune cells could alter their function (7) (8) (9) . Ex vivo-generated macrophages from peripheral blood CD14+ monocytes from RA patients produced higher levels of ATP and mitochondrial activity. Monocytes are the common precursors of macrophages and osteoclasts, and such activation in RA may be linked to bone destruction in this disease (10) . Peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1ɑ) and PGC-1β are part of a group of master regulators of mitochondrial biogenesis and respiration (11) . PGC-1β, but not PGC-1α, is induced during osteoclast differentiation. PGC-1β-deficient mice show osteoclast defects associated with impaired bone resorption, suggesting a role of PGC-1β in osteoclast differentiation and function (12, 13) . However, the contribution of PGC-1β in osteoclast differentiation from osteoclast precursors remains to be studied in RA.
In the current study, we investigated the role of PGC-1β in circulating osteoclast precursors and its contribution to osteoclastogenesis in RA. In addition, the contribution of NFATc1, a critical transcriptional regulator of osteoclastogenesis, was determined (14) . We found an increased nuclear accumulation of PGC-1β in peripheral blood CD14+ monocytes from patients with RA that correlated with the degree of joint destruction. These cells exhibited a strong capacity for osteoclastogenesis, which was increased by overexpression of PGC-1β and decreased by PGC-1β knockdown. The inhibition of NFATc1 activation limited the effect of overexpressed PGC-1β. These results indicated that activation of the PGC-1β/NFATc1 pathway in circulating osteoclast precursors was associated with bone destruction in RA.
PATIENTS AND METHODS
Patients and controls. Forty-two RA patients who fulfilled the 1987 American College of Rheumatology (ACR) revised classification criteria for RA (15) or the ACR/European League Against Rheumatism (EULAR) 2010 classification criteria for RA (16) were recruited from the Department of Rheumatology at Sun Yat-Sen Memorial Hospital from April 2016 to September 2018. Sex-matched healthy volunteers (n = 26) and patients with osteoarthritis (OA) (n = 16) were recruited as controls. The exclusion criteria were being age >65 years; having diabetes mellitus, obesity, severe infection, malignancy, or neurologic disease; or having an overlap with other autoimmune diseases such as lupus, myositis, or scleroderma. The demographic characteristics of the RA patients and controls are summarized in Supplementary Table 1 (available on the Arthritis & Rheumatology web site at http://onlin e libr ary.wiley.com/doi/10.1002/art.40868/ abstract). The study was approved by the Medical Ethics Committee of Sun Yat-Sen Memorial Hospital (SYSEC-2014-LSY-89). All participants provided written informed consent before clinical data collection.
Demographic and clinical data were collected at the time of recruitment as described previously (17, 18) . RA disease activity was assessed using the Disease Activity Score in 28 joints with 4 variables, including C-reactive protein level (19) . Radiographs of bilateral hands, wrists, and feet (anteroposterior view) were performed on all RA patients and assessed with the modified Sharp/ van der Heijde score by 2 experienced observers (J-ZL and L-FC), who were blinded with regard to clinical data (20, 21) . Reliability and agreement were assessed using an intraclass correlation coefficient (ICC); the mean ICC for interobserver agreement was 0.90. Erosive disease was defined according to the 2013 EULAR definition when a cortical break was detected by radiography (22) .
Isolation of peripheral blood CD14+ monocytes.
Peripheral blood mononuclear cells (PBMCs) were isolated from RA patients and OA patients, as well as healthy controls, by using Ficoll-Hypaque density-gradient centrifugation (Sigma-Aldrich). Cells were washed twice with cold phosphate buffered saline (PBS; Gibco), and monocytes were isolated from PBMCs using CD14+ magnetic bead separation (BD Biosciences), following the protocol of the manufacturer. Separated monocytes were stained with phycoerythrin (PE)-anti-CD14 antibody (BD Biosciences) for flow cytometric analysis.
Osteoclast differentiation and bone resorption
assay. For the osteoclast differentiation assay, 1 × 10 6 peripheral blood CD14+ monocytes were cultured in 24-well culture plates in the presence of 100 ng/ml of RANKL and 50 ng/ml of M-CSF (both from PeproTech). Osteoclasts were confirmed by tartrate-resistant acid phosphatase (TRAP) staining and further staining with fluorescein isothiocyanate (FITC)-phalloidin (both from Sigma-Aldrich) to detect F-actin ring using a Leica DMI4000B inverted wide-field fluorescence microscope. Mature osteoclasts were defined as TRAP-positive giant cells including ≥3 nuclei and bands of F-actin-containing podosomes.
For bone resorption assay, bovine cortical bone slices were layered at the bottom of 48-well culture plates, and 5 × 10 5 peripheral blood CD14+ monocytes were seeded onto the slices and cultured in the presence of 100 ng/ml of recombinant human RANKL and 50 ng/ml of M-CSF. Resorption pits on the slices were shown by toluidine blue staining and measured using an ImageJ 1.47 analysis system (NIH).
Immunofluorescence staining. Peripheral blood CD14+ monocytes were plated on 24-well culture plates with coverslips. After incubation for 4 hours, the medium was aspirated and cells were washed twice in PBS, fixed in 4% paraformaldehyde for 15-30 minutes, permeabilized in 0.2% Triton X-100 for 10 min-utes at room temperature for the exposure of intracellular antigen, and blocked in PBS containing 3% bovine serum albumin (BSA; Affymetrix) for 30 minutes. Cells were then washed in PBS 3 times for 10 minutes each time and incubated in PBS containing rabbit anti-human polyclonal antibody against PGC-1β (Bioss) and mouse anti-human CD14 monoclonal antibody (Abcam) or normal rabbit IgG overnight at 4°C. Alexa Fluor 594-conjugated goat anti-rabbit IgG and Alexa Fluor 488-conjugated goat anti-mouse IgG (1:1,000; concentrations of stock solutions 2 mg/ml) (both from Invitrogen) were added and incubated for 1 hour at 37°C. After washing in PBS, the nucleus was stained with DAPI (Sigma-Aldrich) for 3 minutes and coverslips were mounted with ProLong Gold Antifade Reagent (Invitrogen). Images were analyzed using a Zeiss LSM 710 Confocal Imaging System (23) .
Flow cytometric analysis.
Peripheral blood CD14+ monocytes were stained first with PE-conjugated anti-CD14 monoclonal antibody (BD Biosciences) for cell surface antigen. Cells were washed twice with staining wash buffer and centrifuged (1,000 revolutions per minute for 5 minutes) to pellet the cells. They were then resuspended with 100 μl of fixation/permeabilization solution (eBioscience) for 30 minutes at 4°C to expose intracellular antigen. Cells were washed twice with 500 μl of wash buffer and suspended with 100 μl of permeabilization buffer mixed with 1 μl of rabbit anti-human/mouse PGC-1β antibody (Bioss) in the dark for 30 minutes at room temperature. Next, they were washed twice and resuspended with 100 μl of permeabilization buffer mixed with 1 μl of FITC-conjugated anti-rabbit secondary antibody (Invitrogen) in the dark for 20 minutes at room temperature. Stained cells were washed with permeabilization buffer and resuspended with 200 μl of phosphate buffered albumin (0.5% BSA and 0.05% NaN 3 in PBS) before flow cytometric analysis. In each case, staining was compared to that of the appropriately labeled isotype control antibody.
PGC-1β gene silencing or overexpression by lentivirus transfection.
To obtain cell lines with stable silencing or overexpression of PGC-1β, peripheral blood CD14+ monocytes were transfected with PGC-1β sequence-specific short hairpin RNA (shRNA) expression lentivirus or overexpression lentivirus, which were synthesized by Shanghai GeneChem. The target sequences for human PGC-1β knockdown were GCATAGTCTAGGCAAA-GAAAT, marked as Lv-sh-PGC-1β, and shRNA targeting CCTAA-GGTTAAGTCGCCCTCG (noncoding in human) was cloned into the same vector, used as control, and marked as Lv-sh-GFP. Human full-length PGC-1β complementary DNA (cDNA) was cloned into lentiviral vector pLV[Exp] and marked as Lv-PGC-1β, and empty pLV[Exp] vector expressing green fluorescent protein (GFP) only were used as negative control, and referred to as Lv-GFP. The production and transfection of lentivirus were conducted as described previously (24) . Stably transduced cells were selected by addition of puromycin (1 μg/ml) for 48 hours and verified by real-time quantitative poly merase chain reaction (qPCR) and Western blot analysis.
Real-time qPCR analysis. Total RNA was prepared from cells, using RNAiso reagent (Takara). RNA was reverse transcribed into cDNA using a reverse transcript kit (Takara) according to the instructions of the manufacturer. Complementary DNA was amplified by using recombinant Taq DNA polymerase (Takara) and specific oligonucleotide primers of PGC-1β, tumor necrosis factor receptor-associated factor 6 (TRAF6), and β-actin (Supplementary Table 2 , available on the Arthritis & Rheumatology web site at http://onlin elibr ary.wiley.com/doi/10.1002/art.40868/ abstract). SYBR Green-based qPCR was performed using a Roche Light-Cycler 480 sequence detector system (25) .
Western blot analysis. Cytoplasmic or nuclear proteins from human peripheral blood CD14+ monocytes were extracted separately using nuclear protein extraction kits (Pierce). Target proteins from cytoplasm were detected with primary antibodies to TRAP, DC-STAMP, cathepsin K (1:1,000; all from Abcam), matrix metalloproteinase 9 (MMP-9), TRAF6, phospho-p38, p38, phospho-ERK1/2, ERK1/2, phospho-JNK, JNK, and β-tubulin (1:1,000; all from Cell Signaling Technology). Target proteins from nuclei were detected with primary antibodies to NFATc1, c-Fos, c-Jun, and fibrillarin (1:1,000; all from Cell Signaling Technology), as well as PGC-1β (1:1,000; Abcam). Protein bands were visualized using enhanced chemiluminescence (Millipore) plus Western blot detection reagents, followed by exposure to a scanning imager (G:BOX Gel & Blot Imaging Series; Syngene) (26) .
VIVIT treatment of human peripheral blood CD14+ monocytes. VIVIT (MCE) was used as an inhibitor of NFATc1 activation (27) . VIVIT powder was dissolved in Dulbecco's modified Eagle's medium at a concentration of 10 μM. After treatment with 10 μM VIVIT plus 100 ng/ml of recombinant human RANKL and 50 ng/ml of M-CSF for 24 hours, nuclear expression of PGC-1β and NFATc1 in peripheral blood CD14+ monocytes from healthy controls was detected by Western blotting. After treatment with 10 μM VIVIT plus 100 ng/ml of recombinant human RANKL and 50 ng/ml of M-CSF for 21 days, cytoplasmic proteins of DC-STAMP, cathepsin K, TRAP, and MMP-9 in peripheral blood CD14+ monocytes from healthy controls were detected by Western blotting.
Chromatin immunoprecipitation (ChIP).
ChIP was performed using a ChIP assay kit (Cell Signaling Technology) according to the instructions of the manufacturer. Briefly, cells in a 10-cm culture plate were crosslinked with 1% formaldehyde for 10 minutes. Crosslinking was neutralized with 0.2M glycine. Cells were collected and suspended in lysis buffer. Genomic fragments were sonicated to a proper length. Protein-DNA complexes were precipitated with PGC-1β antibody or IgG (Cell Signaling Technology) as a negative control, and anti-RNA polymerase II (Cell Sign-| 1255 aling Technology) antibody as a positive control, overnight at 4°C. The complexes were purified using protein A/G magnetic beads, and the crosslinks were reversed at 68°C. The DNA was then purified by applying the sample to a DNA separation column. The purified DNA was amplified by PCR, and the PCR products were analyzed by electrophoresis on a Gel Red-stained 2% agarose gel. The binding capacity of PGC-1β to the NFATc1 promoter was analyzed by qPCR, and the shear DNA sample served as an input control (28) . Primer sequences used in ChIP-qPCR for NFATc1 were as follows: 5ʹ-CCCCCTAGTAAGCCCTTTCCT-3ʹ (forward) and 5ʹ-GGGAAAGAGTTGAGGGACTTAGAA-3ʹ (reverse).
Dual-luciferase reporter gene assay. Plasmid pcDNA3.1-PGC-1β was purchased from GeneChem. The DNA sequences of NFATc1 were custom synthesized by GeneChem and cloned into a firefly luciferase plasmid. Peripheral blood CD14+ monocytes from healthy controls with 80% confluence in 24-well plates were transfected using Lipofectamine 2000 Reagent (Life Technologies) according to the instructions of the manufacturer. Firefly luciferase plasmid of NFATc1 (0.1 μg) and pcDNA3.1-PGC-1β (0.2 μg, 0.4 μg, and 0.6 μg) were cotransfected with Renilla luciferase vector (Promega) for normalization. Forty-eight hours after transfection, Statistical analysis. All data were analyzed using SPSS, version 13.0. For categorical variables, data were expressed as frequencies and percentages. For continuous variables, data were expressed as the mean ± SD or the median and interquartile range. Parametric data were compared by Student's t-test, while nonparametric data were compared by Mann-Whitney rank sum test. The chi-square test was used for comparison of categorical variables in different groups. The correlation of parametric data was assessed by Pearson's correlation test. P values less than 0.05 were considered significant.
RESULTS
Elevated PGC-1β expression in peripheral blood CD14+ monocytes from RA patients. To assess PGC-1β expression in circulating osteoclast precursors, peripheral blood CD14+ monocytes were isolated from RA patients and sex-matched OA patients and healthy controls. As shown in Figure 1A , the mean ± SD PGC-1β transcript levels were significantly higher in peripheral blood CD14+ monocytes from RA patients than those from OA patients (2.51 ± 0.32 versus 1.20 ± 0.36; P < 0.001) and healthy controls (2.51 ± 0.32 versus 1.00; P < 0.001). Intense PGC-1β expression in the nucleus was visualized by dual-color immunostaining in peripheral blood CD14+ monocytes, and the accumulation of PGC-1β in the nucleus was confirmed by Western blot analysis ( Figures 1B and C) . The expression of PGC-1β protein in RA peripheral blood CD14+ monocytes was detected by flow cytometric analysis of intracellular staining. The mean ± SD mean fluorescence intensity of FITC-conjugated PGC-1β in RA patients was significantly higher than in OA patients (85.32 ± 14.20 versus 11.42 ± 3.10; P < 0.001) and healthy controls (85.32 ± 14.20 versus 1.52 ± 0.24; P < 0.001) ( Figure 1D ). Western blot analysis confirmed the higher PGC-1β accumulation in peripheral blood CD14+ monocytes in RA patients than in OA patients (0.97 ± 0.68 versus 0.52 ± 0.22; P = 0.007) and healthy controls (0.97 ± 0.68 versus 0.30 ± 0.11; P < 0.001) ( Figure 1E ).
Association of PGC-1β expression in monocytes with bone erosion in RA patients.
To investigate the relationship between PGC-1β expression in circulating osteoclast precursors and bone erosion in RA, 30 patients with RA were included for statistical analysis, with 43.3% (13 of 30) having erosive disease (Supplementary Table 3 , available on the Arthritis & Rheumatology web site at http://onlin elibr ary.wiley.com/doi/10.1002/art.40868/ abstract). Nuclear expression of PGC-1β as shown by Western blot analysis in peripheral blood CD14+ monocytes was significantly higher in patients with erosive RA than in patients with nonerosive RA (mean ± SD 1.40 ± 0.76 versus 0.63 ± 0.36; P = 0.006) ( Figure 2A ). Furthermore, there was a positive correlation between PGC-1β protein expression in peripheral blood CD14+ monocytes and total modified Sharp/van der Heijde score (r = 0.410, P = 0.025), joint space narrowing subscore (r = 0.396, P = 0.030), and erosion subscore (r = 0.413, P = 0.023) ( Figure 2B ).
Stronger capacity for osteoclastogenesis in monocytes with elevated PGC-1β.
To investigate a possible link between elevated PGC-1β and increased osteoclastogenesis, peripheral blood CD14+ monocytes obtained from 10 RA patients with erosive disease, 6 RA patients with nonerosive disease, and 6 healthy controls were incubated with RANKL and M-CSF to obtain osteoclasts. The demographic information and clinical features of the 16 RA patients are shown in Supplementary Table 4 (available on the Arthritis & Rheumatology web site at http://onlin elibr ary.wiley.com/doi/10.1002/ art.40868/ abstract). On day 14, the mean ± SD cell of mature osteoclasts in RA patients with or without erosive disease were significantly higher than in healthy controls, as follows: for erosive RA, 36 ± 8 versus 18 ± 4 (P = 0.008), and for nonerosive RA, 28 ± 7 versus 18 ± 4 (P = 0.042). On day 21, the mean ± SD cell counts in RA patients with or without erosive disease were significantly higher than in healthy controls, as follows: for erosive RA, 165 ± 27 versus 82 ± 11 (P < 0.001), and for nonerosive RA, 109 ± 22 versus 82 ± 11 (P = 0.037) ( Figures 2C and  D) . On day 21, the mean ± SD bone resorption lacunae were significantly higher in RA patients with or without erosive disease than in healthy controls, as follows: for erosive RA, 252 ± 32 versus 74 ± 12 μm 2 (P < 0.001), and for nonerosive RA, 135 ± 49 versus 74 ± 12 μm 2 (P = 0.026) ( Figures 2C and E) . The mean ± SD cell counts of mature osteoclasts were significantly higher in RA patients with erosive disease versus those without erosive disease (P = 0.038 and P = 0.002 on days 14 and 21, respectively), as was for day 21, 165 ± 27 versus 109 ± 22 [P = 0.024]) and the mean ± SD pit area of bone resorption lacunae on day 21 (P = 0.006) ( Figures 2C-E) . These results indicate that elevated PGC-1β expression in peripheral blood CD14+ monocytes may be involved in the dysregulation of osteoclastogenesis in RA.
Suppression of osteoclastogenesis by inhibition of PGC-1β.
To explore the role of PGC-1β in osteoclastogenesis in circulating osteoclast precursors, a lentiviral vector with specific PGC-1β sequence was used to knock down PGC-1β gene and protein expression in peripheral blood CD14+ monocytes from RA patients (72-86%) ( Figure 3A) . Expression of DC-STAMP and bone-degrading enzymes cathepsin K, TRAP, and MMP-9 was detected by Western blot analysis. DC-STAMP is an essential regulator of cell fusion among osteoclast precur- Figure 1 for other definitions). Color figure can be viewed in the online issue, which is available at http:// onlinelibrary.wiley.com/doi/10.1002/art.40868/abstract. sors. Cathepsin K is responsible for the degradation of bone collagen, whereas TRAP is correlated with resorption activity of osteoclasts. As a potent gelatinase, MMP-9 is required for matrix solubilization by osteoclasts. Peripheral blood CD14+ monocytes were cultured in M-CSF and RANKL for 21 days, and Western blot analysis showed that knockdown of PGC-1β in these monocytes significantly suppressed the cytoplasmic levels of cathepsin K, TRAP, and MMP-9 (51-82% reduction) ( Figure 3B ). Knockdown of PGC-1β in peripheral blood CD14+ monocytes significantly decreased the number of mature osteoclasts and inhibited bone resorption activity of osteoclasts, as shown by the mean ± SD decreased pit area of bone resorption lacunae on day 21 (for mature osteoclasts, 583 ± 73 versus 69 ± 30 [P < 0.001], and for pit area 725 ± 85 versus 138 ± 21 μm 2 [P < 0.001]) ( Figures 3C-E) . These results indicate that elevated PGC-1β in osteoclast precursors plays an important role in promoting formation of osteoclasts and their bone resorption activity.
Overexpression of PGC-1β and promotion of osteoclastogenesis.
Confirming our hypothesis that elevated PGC-1β promotes osteoclastogenesis in circulating osteoclast precursors, we found that a lentiviral vector with PGC-1β increased the expression of the PGC-1β gene and protein by 1.9-2.6-fold in peripheral blood CD14+ monocytes from healthy controls ( Figure 4A ). Additionally, peripheral blood CD14+ monocytes were cultured in M-CSF and RANKL for 21 days, and Western blot analysis showed that overexpression of PGC-1β in these monocytes significantly increased the cytoplasmic levels of cathepsin K, TRAP, and MMP-9, with a 1.5-1.8-fold elevation ( Figure 4B ). Furthermore, overexpression of PGC-1β significantly increased counts of mature osteoclasts on day 21 and significantly increased bone resorption activity of osteoclasts as measured by the mean ± SD area of bone resorption lacunae on day 21 (for mature osteoclasts, 362 ± 63 versus 184 ± 53 [P = 0.005], and for pit area, 742 ± 53 versus 473 ± 36 μm 2 [P = 0.004]) ( Figures 4C-E) . These results confirmed that PGC-1β is a critical regulator of osteoclastogenesis and that overexpression of PGC-1β leads to excessive osteoclast differentiation and their bone resorption activity.
Promotion of osteoclastogenesis through NFATc1 activation.
To explore the signaling pathway of PGC-1βregulated osteoclastogenesis in circulating osteoclast precursors, peripheral blood CD14+ monocytes with PGC-1β knockdown from RA patients or with PGC-1β overexpression from healthy controls were cultured with M-CSF and RANKL for 24 hours. Western blot analysis showed that knockdown of PGC-1β in peripheral blood CD14+ monocytes from RA patients significantly decreased the expression of nuclear NFATc1 protein. There was no significant difference in cytoplasmic expression of TRAF6, ERK1/2, p-ERK1/2, p38, p-p38, JNK, and p-JNK or nuclear expression of c-Jun and c-Fos between the PGC-1β knockdown and control groups ( Figure 5A ). Conversely, overexpression of PGC-1β in peripheral blood CD14+ monocytes, this time from healthy controls, significantly increased the expression of nuclear NFATc1 protein, but not that of other signaling pathway molecules ( Figure 5B) .
To test whether NFATc1 signaling plays a critical role in PGC-1β-mediated osteoclastogenesis, activation of NFATc1 was inhibited by VIVIT, which selectively inhibits calcineurin-mediated dephosphorylation of NFAT. Combined with 50 ng/ml of M-CSF and 100 ng/ml of RANKL for 24 hours, short-term treatment with 10 μM of VIVIT significantly inhibited nuclear translocation of NFATc1, but not that of PGC-1β ( Figure 5C ). Combined with M-CSF and RANKL for 21 days, long-term treatment with VIVIT significantly inhibited the cytoplasmic levels of cathepsin K, TRAP, and MMP-9. It also limited the effect of overexpressed PGC-1β on promoting the expression of cathepsin K, TRAP, and MMP-9 in peripheral blood CD14+ monocytes from healthy controls (Figure 5D ). These results suggest that PGC-1β promotes osteoclastogenesis through activation of NFATc1.
Binding of PGC-1β to NFATc1 promoter and transcriptional activation. In a qPCR analysis to further explore whether PGC-1β directly regulates NFATc1 transcription, PGC-1β increased the level of NFATc1 messenger RNA in peripheral blood CD14+ monocytes (data not shown). Dualcolor immunostaining showed a clear NFATc1 and PGC-1β colocalization signal in the nucleus of peripheral blood CD14+ monocytes from RA patients, whereas the PGC-1β nuclear signal was markedly lower in cells from healthy controls, and NFATc1 was localized mostly to cytoplasm ( Figure 6A ). ChIP assay showed that a markedly higher amount of chromosomal DNA containing the NFATc1 promoter was immunoprecipitated with an anti-PGC-1β antibody compared to control IgG ( Figure 6B ). ChIP-qPCR analysis confirmed the immunoprecipitation of PGC-1β and the NFATc1 promoter ( Figure 6C ), which indicated that PGC-1β binds to the NFATc1 promoter region. Dual-luciferase reporter gene assay showed that overexpressed PGC-1β in the peripheral blood CD14+ monocytes from healthy controls increased the transcriptional activity of NFATc1 in a dose-dependent manner ( Figure 6D ), which suggested that PGC-1β activates NFATc1 transcription.
DISCUSSION
Excessive bone resorption by osteoclasts is the major cause of bone erosion in RA. Cytokines, such as tumor necrosis factor, interleukin-1β (IL-1β), IL-6, and IL-17, are effective triggers of bone resorption and some are now targeted in the clinic with inhibitors showing an effect on bone destruction (29) (30) (31) . These cytokines induce osteoclast differentiation directly or indirectly by increasing the expression of RANKL, which leads to an increase | 1261 Figure 5 . Promotion of osteoclastogenesis by PGC-1β through the NFATc1 pathway. A, Expression of tumor necrosis factor receptorassociated factor 6 (TRAF6), MAPK, activator protein 1 (AP-1), and NFATc1 signaling pathways detected by Western blot analysis following stable knockdown of PGC-1β in PB CD14+ monocytes from RA patients for 24 hours. B, Expression of TRAF6, MAPK, AP-1, and NFATc1 pathways detected by Western blot analysis following stable overexpression of PGC-1β in PB CD14+ monocytes from healthy controls for 24 hours. C, Expression of PGC-1β and NFATc1 detected by Western blot analysis in PB CD14+ monocytes from healthy controls for 24 hours following PGC-1β overexpression and inhibition of NFATc1. D, DC-STAMP, cathepsin K, tartrate-resistant acid phosphatase (TRAP), and matrix metalloproteinase 9 (MMP-9) expression detected by Western blot analysis in PB CD14+ monocytes from healthy controls for 21 days following PGC-1β overexpression and inhibition of NFATc1. Data were summarized from 3 independent experiments. Bars show the mean ± SD. * = P < 0.05; ** = P < 0.01; *** = P < 0.001, by Student's t-test. NC = negative control; lv-sh-GFP = short hairpin RNA expression lentivirus expressing green fluorescent protein; lv-sh-PGC-1β = shRNA expression lentivirus for PGC-1β knockdown; M-CSF = macrophage colonystimulating factor; NS = not significant (see Figure 1 for other definitions). Color figure can be viewed in the online issue, which is available at http://onlinelibrary.wiley.com/doi/10.1002/art.40868/abstract. in osteoclast differentiation and bone resorption activity, and subsequent bone erosion (32) (33) (34) . Joint damage can be found in patients who have had RA for only a short time, and studies have shown enhanced levels of bone metabolism markers in RA patients with preclinical disease, which suggests that bone erosion might happen before the onset of clinical inflammation (35, 36) . Our in vitro study also showed that peripheral blood CD14+ monocytes from RA patients, especially with erosive disease, had a stronger capability had differentiating into osteoclasts and higher bone resorption activity than cells from healthy controls. Therefore, monocytes preexposed to inflammation in bone marrow and exposed to circulating cytokines exhibit intracellular dysregulation leading to increased osteoclast differentiation and activation.
PGC-1β plays important roles in regulating energy metabolism and cytokine signaling pathways and is mainly recognized Figure 6 . Activation of transcription by the binding of PGC-1β to the NFATc1 promoter. A, Representative immunofluorescence staining with NFATc1, PGC-1β, and DAPI in PB CD14+ monocytes from healthy controls and RA patients. Original magnification × 1,000. B, Analysis, by chromatin immunoprecipitation (ChIP) and electrophoresis, of NFATc promoter status of IgG, RNA polymerase II (RNA Pol-II), and PGC-1β in PB CD14+ monocytes from healthy controls and RA patients. C, Analysis, by ChIP followed by quantitative polymerase chain reaction, of NFATc promoter status of IgG, RNA polymerase II, and PGC-1β in PB CD14+ monocytes from RA patients. D, Luciferase activity of the NFATc1 promoter region (shown as fold induction relative to that with the empty pcDNA3.1) after cotransfection with plasmids NFATc1-luc and pcDNA3.1-PGC-1β in PB CD14+ monocytes from healthy controls. Data in C and D were summarized from 3 independent experiments. Bars show the mean ± SD. ** = P < 0.01; *** = P < 0.001, by Student's t-test. E, Illustration of a novel PGC-1β/NFATc1 pathway mediating excessive osteoclastogenesis in RA. M-CSF = macrophage colony-stimulating factor; MMP-9 = matrix metalloproteinase 9; TRAP = tartrate-resistant acid phosphatase (see Figure 1 for other definitions).
| 1263 as a mitochondrial and energy regulatory protein. Earlier studies of PGC-1β focused mainly on metabolic diseases such as hyperlipidemia and diabetes mellitus (37, 38) . We previously found that elevated PGC-1β levels in RA fibroblast-like synoviocytes promoted their proinflammatory effect and RANKL secretion (24) . We then proposed that PGC-1β might play important roles in osteoclastogenesis in RA. In the present study, we found elevated nuclear expression of PGC-1β protein in peripheral blood CD14+ monocytes from RA patients, especially those patients with erosive disease. This expression was positively correlated with radiographic scores. Further studies showed that elevated PGC-1β in RA monocytes promoted osteoclast differentiation and their bone resorption activity. These results implied that PGC-1β in circulating osteoclast precursors might be involved in RA osteoclastogenesis.
The canonical RANKL signaling pathway inducing osteoclasts involves TRAF6. In the microenvironment of a local joint in RA, large quantities of RANKL bind to RANK on the surface of osteoclast precursors, leading to the activation of adaptor molecules such as TRAF6, which is critical for osteoclast differentiation and activation (39) . Downstream signaling pathways from TRAF6 finally activate NFATc1, the master regulator of osteoclastogenesis. Deficiency of Nfatc1 results in complete loss of osteoclastic bone resorption (40, 41) . NFATc1 induces its target genes to regulate differentiation, cell fusion, and function of osteoclasts (39) . In this study, knockdown or overexpression of PGC-1β in peripheral blood CD14+ monocytes resulted in decreased or increased expression of NFATc1, and of TRAP, cathepsin K and MMP-9, but not of TRAF6. Further inhibition of NFATc1 activation limited the role of PGC-1β in the expression of these genes. These results indicate that PGC-1β might act as an upstream regulator of NFATc1, but not TRAF6.
PGC-1β positively regulates both mitochondrial biogenesis and differentiation in osteoclasts. PGC-1β alone, or NFATc1 co-overexpression with PGC-1β in RelB −/− cells, allowed osteoclast differentiation but did not rescue mitochondrial biogenesis (42) , suggesting that PGC-1β/NFATc1 regulation of osteoclast differentiation may occur through a mechanism other than the mitochondrial function of PGC-1β. The role of PGC-1β in regulating osteoclastogenesis was confirmed by global deletion of the PGC-1β gene in mice, leading to increased bone mass and compromised mitochondrial biogenesis in osteoclasts (43) . In Tie2-Cre mice with conditionally deleted PGC-1β in myeloid lineage cells, the number of osteoclasts was decreased (12) . Consistent with these findings, our results clearly showed that, in RA monocytes, PGC-1β directly binds to the promotor of NFATc1 and regulates its transcription.
In conclusion, our findings provide the first evidence that PGC-1β in circulating osteoclast precursors regulates osteoclastogenesis in RA, through mechanisms involving interactions in the PGC-1β/NFATc-1 pathway. These results indicate that PGC-1β in peripheral blood CD14+ monocytes might be a promising therapeutic target for RA and other diseases associated with osteoclast activation, ranging from arthritis to bone metastasis ( Figure 6E ).
